Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/77146
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAhizechukwu C. Ekeen_US
dc.contributor.authorKensuke Shojien_US
dc.contributor.authorBrookie M. Besten_US
dc.contributor.authorJeremiah D. Momperen_US
dc.contributor.authorAlice M. Steken_US
dc.contributor.authorTim R. Cresseyen_US
dc.contributor.authorMark Mirochnicken_US
dc.contributor.authorEdmund V. Capparellien_US
dc.date.accessioned2022-10-16T07:23:41Z-
dc.date.available2022-10-16T07:23:41Z-
dc.date.issued2021-03-01en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-85101760144en_US
dc.identifier.other10.1128/AAC.02168-20en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101760144&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/77146-
dc.description.abstractPharmacokinetics of drugs can be affected by physiologic changes during pregnancy. Our aim was to assess the influence of covariates on tenofovir (TFV) pharmacokinetics in pregnant and postpartum women receiving tenofovir disoproxil fumarate (TDF). Population pharmacokinetic parameter estimates and the influence of covariates were assessed using nonlinear mixed-effects modeling (NONMEM 7.4). Forty-six women had intensive pharmacokinetic evaluations during the second and third trimesters of pregnancy, with another evaluation postpartum. A two-compartment pharmacokinetic model with allometric scaling for body weight and first-order absorption best described the tenofovir plasma concentration data. Apparent oral clearance (CL/F) and volume of distribution at steady state (Vss/F) were increased during pregnancy. Weight, serum creatinine (SCr), pregnancy, albumin, and age were associated with TFV CL/F during univariate assessment, but in the multivariate analysis, changes in CL/F and Vss/F were only associated with increased body weight and enhanced renal function. Due to greater weight and lower SCr during pregnancy, CL/ F was 28% higher during pregnancy than postpartum. In the final model, CL/F (liters per hour) was described as 2.07 x (SCr/0.6)0.65 x weight0.75, with a low between-subject variability (BSV) of 24%. The probability of target attainment (proportion exceeding area under the concentration-time curve of .1.99mg h/ml, the 10th percentile of average TFV exposure for nonpregnant historical controls) was 68%, 80%, 87%, and 93% above the target with 300 mg, 350 mg, 400 mg, and 450mg of TDF, respectively, during pregnancy and 88%, 92%, 96%, and 98% above the target with same doses in postpartum women. Dose adjustment of TDF during pregnancy is not generally warranted, but any modification should be based on weight and renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT00042289.).en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePopulation pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarateen_US
dc.typeJournalen_US
article.title.sourcetitleAntimicrobial Agents and Chemotherapyen_US
article.volume65en_US
article.stream.affiliationsSkaggs School of Pharmacy & Pharmaceutical Sciencesen_US
article.stream.affiliationsNational Center for Child Health and Developmenten_US
article.stream.affiliationsUniversity of California, San Diegoen_US
article.stream.affiliationsUniversity of Liverpoolen_US
article.stream.affiliationsKeck School of Medicine of USCen_US
article.stream.affiliationsBoston University School of Medicineen_US
article.stream.affiliationsJohns Hopkins Bloomberg School of Public Healthen_US
article.stream.affiliationsJohns Hopkins School of Medicineen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.